共 50 条
- [41] Comparing Recurrence Rates of Clostridioides difficile Infection in Patients With Inflammatory Bowel After Low, Medium, and High Doses of Oral Vancomycin for the Initial Episode of CDI AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S760 - S760
- [42] Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
- [43] Real World Experience of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Mayo Clinic Experience AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S141 - S141
- [44] Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile infection INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2023, 44 (09): : 1403 - 1409
- [47] Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies Infectious Diseases and Therapy, 2020, 9 : 481 - 494
- [48] Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):